SCM
VNDA icon

Stevens Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Stevens Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-30,268
Closed -$253K – 1145
2016
Q1 		$253K Buy
+30,268
New +$248K 0.01% 713
2013
Q4 		– Sell
-21,274
Closed -$233K – 1246
2013
Q3 		$233K Buy
+21,274
New +$227K 0.01% 862

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's VNDA Position: Q2 2016 in Review

Stevens Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2016, closing a stake of 30,268 shares — an estimated $253K sold.

Stevens Capital Management first reported a position in VNDA in Q3 2013 and held it in 2 quarters. The position peaked at $253K in Q1 2016. 115 funds tracked by Wall St. Rank hold VNDA as of Q2 2016.

  • Stevens Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Stevens Capital Management sold 30,268 Vanda Pharmaceuticals shares in Q2 2016, an estimated $253K.
  • Stevens Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Stevens Capital Management's Vanda Pharmaceuticals position peaked at $253K in Q1 2016.
  • 115 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.